EntryPoint Capital’s United Therapeutics UTHR Stock Holding History

EntryPoint Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-350	Closed	-$77K	–	1778
2023 Q4	$77K	Buy	+350	New	+$80.7K	0.07%	514

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

EntryPoint Capital's UTHR Position: Q1 2024 in Review

EntryPoint Capital sold out of United Therapeutics (UTHR) in Q1 2024, closing a stake of 350 shares — an estimated $77K sold.

EntryPoint Capital first reported a position in UTHR in Q4 2023 and held it in 1 quarter. The position peaked at $77K in Q4 2023. 525 funds tracked by Wall St. Rank hold UTHR as of Q1 2024.

EntryPoint Capital reported no remaining United Therapeutics position as of Q1 2024 after selling out during the quarter.
EntryPoint Capital sold 350 United Therapeutics shares in Q1 2024, an estimated $77K.
EntryPoint Capital first reported a position in United Therapeutics in Q4 2023 and held it in 1 quarter.
EntryPoint Capital's United Therapeutics position peaked at $77K in Q4 2023.
525 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2024.

Based on EntryPoint Capital's 13F filing for Q1 2024, filed 14 May 2024.